The FDA approved GSK’s Hibsago (bepirovirsen) for chronic hepatitis B on October 20, 2026, with a 19 percent functional cure rate in the B-Well Phase 3 program.
Last updated: October 21, 2026
The FDA approved GSK’s Hibsago (bepirovirsen), a first in class antisense oligonucleotide, for chronic hepatitis B on October 20, 2026. In the pooled B-Well Phase 3 trials, 19 percent of treated patients achieved functional cure versus zero on placebo.
This briefing covers the Hibsago approval and what it means for the hepatitis B market, Disc Medicine’s $450 million offering, Rapport’s Phase 2 bipolar mania readout, Alcon’s $550 million Neurotech acquisition, Intuitive Surgical and Telix third quarter results, and the day’s other verified developments from October 20, 2026.
What did the FDA approve Hibsago (bepirovirsen) for?
The FDA approved Hibsago in combination with nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI) therapy for adults with chronic hepatitis B who do not have cirrhosis, have been on NrtI therapy for at least six months with suppressed HBV DNA, and have HBsAg levels of 3,000 IU/mL or below.
GSK announced the approval after the market close on Tuesday, October 20, 2026. Bepirovirsen is a first in class antisense oligonucleotide given as a six month treatment course, with the option of self administration after the first dose. The approval came under Priority Review with Breakthrough Therapy designation, and follows an earlier approval in Japan. GSK chief scientific officer Tony Wood said that “for the first time, with Hibsago, US patients have the potential to achieve functional cure after a six-month treatment course.” The company says about 1.7 million people in the US live with chronic hepatitis B.
The label is deliberately narrow. Eligibility requires an FDA authorized test to confirm HBsAg at or below 3,000 IU/mL, and the drug is contraindicated in patients with cirrhosis, acute hepatic impairment, or platelet counts below 100 x 10^9/L. That segmentation matters commercially: the trial data show response rates nearly double in patients who start with lower antigen levels.
How well did bepirovirsen perform in the B-Well Phase 3 trials?
In the pooled B-Well 1 and B-Well 2 trials, 19 percent of bepirovirsen patients achieved functional cure versus zero of 614 placebo patients. In the prespecified subgroup starting at HBsAg of 1,000 IU/mL or below, the rate rose to 26 percent.
Functional cure means HBV DNA and hepatitis B surface antigen stay undetectable for at least 24 weeks after all treatment stops, including the background NrtI. GSK’s release says current standard of care typically achieves less than a 1 percent functional cure rate after a year of treatment. Both trials, run across 29 countries, met their primary endpoints.
| B-Well pooled result | Bepirovirsen | Placebo |
|---|---|---|
| Functional cure, overall population | 19% (233 of 1,220) | 0 (0 of 614) |
| Functional cure, baseline HBsAg ≤1,000 IU/mL | 26% (200 of 768) | 0 (0 of 393) |
| HBsAg ≤100 IU/mL at week 72 (exploratory), overall | 49% (598 of 1,220) | Not reported |
| HBsAg ≤100 IU/mL at week 72 (exploratory), ≤1,000 subgroup | 62% (476 of 768) | Not reported |
All figures are from GSK’s October 20 press release, which is the primary source for the approval and the trial data.
What are Hibsago’s safety warnings?
Hibsago carries a boxed warning for hepatic flares on treatment and for thrombocytopenia. It is contraindicated in patients with platelet counts below 100 x 10^9/L and in patients with acute hepatic impairment or cirrhosis.
The label also warns on omental infarction associated with improper injection technique: the two injections that make up each dose must be separated by at least two inches, with sites rotated weekly. The most common adverse reactions, at 10 percent or higher, were injection site reactions, pyrexia, fatigue, and headache. GSK did not state US launch timing or price in the release, and said further regulatory decisions in other geographies are expected in the coming months.
What does the Hibsago approval mean for Ionis?
GSK licensed bepirovirsen from Ionis Pharmaceuticals and developed it in collaboration with the company. Ionis announced the approval in its own release on Tuesday evening, but neither release disclosed royalty or milestone terms, so the economics to Ionis are not public in the approval documents.
Wednesday, October 21 is the first session in which GSK and Ionis shares can react to the approval, which crossed at 7:58 pm Eastern on Tuesday. GSK had already closed up 2.4 percent at $50.63 on Tuesday, its first session after Monday’s accelerated approval of Jemperli in locally advanced rectal cancer. GSK’s Tuesday also included a second deal event: its KRAS-EGFR antibody conjugate license with HUTCHMED formally closed, with the $110 million upfront payment due shortly.
Why did Disc Medicine raise $450 million the day after its Phase 3 win?
Disc Medicine priced an upsized $450 million public offering on Tuesday night, one day after reporting that bitopertin swept its Phase 3 APOLLO trial in erythropoietic protoporphyria. The deal was launched Monday at a proposed $350 million and grew by $100 million in a day.
| Term | Detail |
|---|---|
| Shares | 6,000,000 common shares |
| Price | $75.00 per share |
| Gross proceeds | $450 million before fees, assuming no overallotment exercise |
| Overallotment option | Up to 900,000 additional shares, 30 days |
| Expected closing | October 22, 2026 |
| Bookrunners | Jefferies, Leerink Partners, Morgan Stanley, Cantor |
| Use of proceeds | Bitopertin commercialization in EPP and XLP, pipeline, working capital |
The $75.00 clearing price sits 5.0 percent below Monday’s $78.93 close and 5.6 percent below Tuesday’s $79.48 close, our arithmetic from exchange settled closes. Disc shares added 0.7 percent in Tuesday’s regular session before the pricing crossed after hours; Wednesday is the first session to react to the final terms. The offering follows Monday’s APOLLO topline, in which bitopertin reduced protoporphyrin IX by 41.4 percent and the company guided to an NDA resubmission by the end of 2026.
Did Rapport’s RAP-219 succeed in bipolar mania?
Yes on the statistics, with a debate on the magnitude. RAP-219 met the primary endpoint of its Phase 2 bipolar mania trial with a 3.1 point placebo adjusted improvement in YMRS total score at week three, p=0.045, but the effect size came in below the four point bar management itself had described as clinically meaningful.
| Measure | Result |
|---|---|
| Enrollment | 253 adults, bipolar I disorder, acute manic episode, inpatient |
| Dose | 0.75 mg once daily for three weeks |
| Primary: YMRS vs placebo, week 3 | 3.1 point LS mean improvement, p=0.045 (15.4 vs 12.3 point reductions from baseline) |
| YMRS separation by week | 0.9 (week 1), 2.2 (week 2), 3.1 (week 3) |
| Secondary: CGI-BP mania severity | 0.4 point improvement vs placebo, p=0.024 |
| Safety | TEAEs 51.6% vs 52.8% placebo; no serious adverse events; discontinuations for TEAEs 3.2% vs 0.8% |
Rapport said no orthostatic hypotension, akathisia, or extrapyramidal symptoms were reported, a tolerability profile that differs from antipsychotics. The company plans an end of Phase 2 FDA meeting in the first quarter of 2027 and two Phase 3 trials in acute bipolar mania beginning in the second half of 2027, funded by $436.1 million in cash as of June 30 that it expects to last into the second half of 2029.
The debate: chief executive Abe Ceesay had called a four point placebo adjusted YMRS improvement the clinically meaningful threshold at an investor event last month, and William Blair analysts note approved agents have shown four to seven points, per Fierce Biotech. The same analysts argue the 42 percent improvement from baseline in the treatment arm lands within the range of approved therapies. The market’s first verdict was close to a coin flip: Rapport traded between $26.73 and $31.31 on Tuesday and settled at $29.37, up 2.7 percent on a day the XBI rose 3.6 percent.
What did Alcon buy in the Neurotech acquisition?
Alcon paid $550 million to acquire Neurotech Pharmaceuticals, the maker of ENCELTO, the only FDA approved treatment for idiopathic Macular Telangiectasia Type 2. The deal, announced Tuesday after the close, is completed, with undisclosed contingent payments possible on commercial milestones.
ENCELTO (revakinagene taroretcel-lwey) is an encapsulated cell therapy implanted surgically into the vitreous, where it continuously releases ciliary neurotrophic factor. The FDA approved it in March 2025 under Priority Review with Orphan Drug designation. Alcon cites roughly 25,000 diagnosed MacTel patients in the US, with 2,000 to 3,000 new diagnoses a year, and expects the deal to be modestly accretive to sales growth and slightly dilutive to core earnings per share in 2027, then accretive after that. For Alcon, it is a move deeper into retinal therapeutics beyond its surgical and vision care base.
How did Intuitive Surgical perform in the third quarter of 2026?
Intuitive Surgical reported third quarter revenue of $3.05 billion, up 22 percent from $2.51 billion a year earlier, with worldwide procedures up about 15 percent. GAAP earnings fell on a $450 million antitrust settlement charge.
| Intuitive Surgical Q3 2026 | Result | Year earlier |
|---|---|---|
| Revenue | $3,048.7 million (+22%) | $2,505.1 million |
| Worldwide procedures | About +15% (da Vinci +14%, Ion +31%) | Not restated |
| da Vinci 5 placements | 315 | 240 |
| Total da Vinci placements | 546 | 427 |
| GAAP diluted EPS | $1.49 | $1.95 |
| Non GAAP diluted EPS | $3.00 | $2.40 |
The GAAP decline traces to a $450 million pretax antitrust settlement charge, worth $0.99 per diluted share, which still requires preliminary and final court approval. The company also booked a $22 million tariff refund benefit and repurchased $2.94 billion of stock in the quarter. Full year guidance calls for worldwide da Vinci procedure growth of about 14 to 15 percent, expected closer to the midpoint, with non GAAP gross margin of 68.7 to 69.3 percent including a 0.9 percent tariff impact. The results crossed after Tuesday’s close, so Wednesday is the first reaction session.
What did Telix report for the third quarter?
Telix reported third quarter revenue of $245 million, up 19 percent year over year, with Precision Medicine revenue of $201 million up 30 percent, and set December 1, 2026 as the expected date for the shareholder meeting on its ITM merger.
Telix said revenue is tracking in line with the upper end of its full year guidance of $950 to $970 million plus $40 million of other income, and narrowed research and development guidance to $240 to $260 million. The ITM acquisition remains the structural story: $1.65 billion upfront on a cash free, debt free basis, with about $1.25 billion payable in Telix shares as ADRs and up to $700 million contingent on ITM-11 approvals and sales milestones, subject to the shareholder vote now expected December 1. The company also said a resubmission of the Zircaix kidney cancer imaging BLA is planned in the near term after a corrected Complete Response Letter, and that enrollment in the 350 patient BiPASS prostate cancer trial is complete. The release carries a Melbourne dateline of October 21 and crossed Tuesday evening US time.
What else happened in life sciences on October 20, 2026?
A capital markets cluster, a closed GSK license, and a dated set of catch up items round out the day.
HUTCHMED and GSK closed their KRAS-EGFR license. The September 3 agreement for HMPL-A830, a first in class antibody targeted therapy conjugate carrying a KRAS inhibitor payload on an anti EGFR antibody, formally closed following antitrust reviews. HUTCHMED expects the $110 million upfront payment shortly and can earn up to $1.185 billion in milestones plus tiered royalties, with GSK holding worldwide rights outside Greater China.
Gilead’s oral alpha4beta7 hit in ulcerative colitis. Presented Monday at UEG Week in Barcelona, the Phase 2 SWIFT study of emvistegrast in 238 patients showed 66 percent clinical response at the 200 mg dose versus 37 percent on placebo and 31 percent clinical remission versus 8 percent, per Gilead’s statement and BioSpace. The dose response was imperfect, with the 75 mg arm underperforming the 25 mg arm, which Gilead attributed to potential study noise. Phase 3 starts next year.
The financing window stayed open. Lycia Therapeutics set terms for a $228 million Nasdaq IPO to fund a food allergy rival to Xolair, per Fierce Biotech. Teknova priced a $40 million offering, and Surrozen closed a $95.1 million second tranche of its March 2025 private placement. Ambrose Healthcare signed a deal worth up to $181 million for former Pfizer target AM-Pharma, per Fierce Biotech.
Elsewhere: Ascentage Pharma’s lisaftoclax won breakthrough therapy designation in China for treatment naive CLL/SLL, and AstraZeneca tapped Oracle to improve clinical trial recruitment, per Fierce Biotech. Checked and still absent as of Tuesday night: a City Therapeutics IPO closing release, an Electra Therapeutics overallotment disclosure, any ruling in the October 340B rebate pilot litigation (searches continue to surface only the December 2025 rulings against the separate version one pilot), and any Atebrioz list price documentation.
Which stocks moved on the day’s news?
The sector rallied while the newest floats faded, and the day’s biggest fundamental winners reported after the close.
| Ticker | Oct 20 close | Move | Context |
|---|---|---|---|
| RAPP | $29.37 | +2.7% | Phase 2 mania win below the four point bar; traded $26.73 to $31.31 |
| GSK | $50.63 | +2.4% | First session after the Jemperli approval; Hibsago crossed after the close |
| IRON | $79.48 | +0.7% | $450 million offering priced at $75.00 after the close |
| IAM | $16.01 | −2.1% | Back to its $16.00 offer price six sessions after debut; no disclosure found |
| XBI | $153.24 | +3.6% | Sector rally; SPY +0.3% |
Closes are exchange settled; percentage moves are our arithmetic against Monday’s settled closes. The fresh IPO cohort lagged a strong tape: City Therapeutics slipped 2.9 percent to $20.83, RTSN eased 0.9 percent to $16.18, and TRXB fell 2.4 percent to $14.44.
Frequently asked questions
What is Hibsago (bepirovirsen)?
Hibsago is GSK’s antisense oligonucleotide for chronic hepatitis B, approved by the FDA on October 20, 2026. It is given as a six month course alongside standard NrtI therapy and is the first in its class for this disease.
Who is eligible for Hibsago under the FDA label?
Adults with chronic hepatitis B who do not have cirrhosis, have taken NrtI therapy for at least six months with suppressed HBV DNA, and have HBsAg at or below 3,000 IU/mL as measured by an FDA authorized test.
What is a functional cure in hepatitis B?
Functional cure means both HBV DNA and hepatitis B surface antigen remain undetectable for at least 24 weeks after all treatment stops. It is not viral eradication, but it allows patients to stop lifelong suppressive therapy.
What functional cure rate did bepirovirsen achieve?
19 percent of all treated patients in the pooled B-Well Phase 3 trials, 233 of 1,220, versus zero of 614 on placebo. Patients starting with HBsAg at or below 1,000 IU/mL reached 26 percent.
Does Hibsago have a boxed warning?
Yes. The boxed warning covers hepatic flares on treatment and thrombocytopenia. The drug is contraindicated with platelet counts below 100 x 10^9/L and in acute hepatic impairment or cirrhosis.
What does the approval mean for Ionis Pharmaceuticals?
GSK licensed bepirovirsen from Ionis, which stands to receive economics that neither company disclosed in the approval releases. Wednesday is the first trading session for both stocks to react to the approval.
At what price did Disc Medicine’s offering price?
$75.00 per share for 6,000,000 shares, for $450 million gross, upsized from a proposed $350 million. That is 5.0 percent below Monday’s close. The offering is expected to close October 22, 2026.
Did Rapport’s RAP-219 bipolar mania trial meet its primary endpoint?
Yes. RAP-219 improved YMRS total score by a placebo adjusted 3.1 points at week three, p=0.045, and the key secondary endpoint also reached significance. The effect size fell short of the four point threshold management had called clinically meaningful.
Why are analysts debating Rapport’s result?
Approved antimanic agents have shown placebo adjusted YMRS improvements of four to seven points, per William Blair via Fierce Biotech. Rapport’s 3.1 points is below that range, though the clean tolerability profile, with no serious adverse events, supports a differentiated positioning into Phase 3.
How much did Alcon pay for Neurotech?
$550 million paid at closing, with undisclosed contingent payments possible on commercial milestones. The acquisition is completed.
What is ENCELTO and what does it treat?
ENCELTO is an encapsulated cell therapy implanted in the eye that continuously releases ciliary neurotrophic factor. It is the only FDA approved treatment for idiopathic Macular Telangiectasia Type 2, approved in March 2025.
How much revenue did Intuitive Surgical report in Q3 2026?
$3,048.7 million, up 22 percent from $2,505.1 million a year earlier, with worldwide procedures up about 15 percent and 315 da Vinci 5 systems placed.
Why did Intuitive’s GAAP earnings fall despite 22 percent revenue growth?
A $450 million pretax antitrust settlement charge cut GAAP diluted EPS to $1.49 from $1.95. Excluding items, non GAAP EPS rose to $3.00 from $2.40. The settlement still requires court approval.
When is Telix’s shareholder vote on the ITM merger?
Telix expects the general meeting on December 1, 2026, Australian time. The deal carries $1.65 billion upfront with up to $700 million in contingent payments.
When does Abbott report third quarter results?
Wednesday, October 21, 2026, before the US market opens, with the call at 8:00 am Central. It is the first large cap medtech print of the quarter and the first earnings test of whether companies holding real data and real revenue get paid in this market.
Sources
Primary sources, October 20, 2026: GSK press release, “Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B” (Business Wire, 7:58 pm ET); Ionis Pharmaceuticals release on the Hibsago approval (9:20 pm ET); Disc Medicine offering pricing release (GlobeNewswire, 8:52 pm ET); Rapport Therapeutics RAP-219 Phase 2 topline release (GlobeNewswire, 6:00 am ET); Alcon acquisition release (Business Wire, 4:35 pm ET); Intuitive Surgical third quarter 2026 results release (GlobeNewswire); Telix Pharmaceuticals third quarter 2026 results release (GlobeNewswire, Melbourne dateline October 21); HUTCHMED license closing release (GlobeNewswire, 8:00 pm ET); Surrozen private placement tranche closing release; Teknova offering pricing release; Ascentage Pharma breakthrough designation release. October 19: Gilead company statement on the Phase 2 SWIFT study of emvistegrast.
Trade press, attributed: Fierce Biotech (Rapport analyst reaction, Lycia IPO terms, Ambrose Healthcare and AM-Pharma, AstraZeneca and Oracle); BioSpace (Gilead emvistegrast coverage). Market closes are exchange settled prices; percentage moves are our arithmetic.
